Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 13, 2022
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
[ Wed, Jul 13th 2022
] - WOPRAI
Luke Sergott Maintained (TWST) at Buy with Increased Target to $45 on, Jul 13th, 2022
Luke Sergott of Barclays, Maintained "Twist Bioscience Corporation" (TWST) at Buy with Increased Target from $40 to $45 on, Jul 13th, 2022.
Luke has made no other calls on TWST in the last 4 months.
There is 1 other peer that has a rating on TWST. Out of the 1 peers that are also analyzing TWST, all agrees with Luke's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Sykes of "Goldman Sachs" Maintained at Hold with Decreased Target to $55 on, Wednesday, April 13th, 2022
